Population pharmacokinetics of amikacin in a Korean clinical population

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 6, 2011, Pages 371-381

  Jang, S B ^a   Lee, Y J ^a   Park, M S ^a   Song, Y G ^a   Kim, J H ^a   Kim, H K ^a   Ahn, B S ^a   Park, Kyungsoo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Amikacin; Aminoglycoside; Antibiotics; Korean patients; Optimal dosage regimen; Pharmacokinetics

Indexed keywords

AMIKACIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHOLECYSTITIS; COMPUTER PROGRAM; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; STEADY STATE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 79959447003     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201520     Document Type: Article

References (43)

1. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol. 1995; 39: 597-603.
2. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984; 77: 657-662. (Pubitemid 14047595)
3. Langhendries JP, Battisti O, Bertrand JM, François A, Darimont J, Ibrahim S, Tulkens PM, Bernard A, Buchet JP, Scalais E. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther. 1993; 20: 220-230.
4. Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol. 1998; 53: 337-341. (Pubitemid 28067974)
5. Contreras AM, Gamba G, Cortés J, Santiago Y, Nares F, Jimenez-Sanchez G, Bobadilla J, López G, Valadez A, Espinosa A, et al. Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity. Antimicrob Agents Chemother. 1989; 33: 973-976. (Pubitemid 19146597)
6. Jaresko GS, Boucher BA, Dole EJ, Tolley EA, Fabian TC. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clin Pharm. 1989; 8: 43-48.
7. Townsend PL, Fink MP, Stein KL, Murphy SG. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med. 1989; 17: 154-157. (Pubitemid 19066574)
8. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs. 1994; 47: 902-913.
9. Garraffo R, Iliadis A, Cano JP, Dellamonica P, Lapalus P. Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin. J Pharm Sci. 1989; 78: 753-757. (Pubitemid 20101924)
10. Tréluyer JM, Merlé Y, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002; 46: 1381-1387.
11. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004; 23: 291-295.
12. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997; 41: 1115-1119. (Pubitemid 27194194)
13. Lugo-Goytia G, Castañeda-Hernández G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother. 2000; 34: 1389-1394.
14. Lugo G, Castañeda-Hernández G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit. 1997; 19: 271-276. (Pubitemid 28053480)
15. Gilman TM, Brunnemann SR, Segal JL. Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodied patients. Antimicrob Agents Chemother. 1993; 37: 93-99. (Pubitemid 23019176)
16. Triginer C, Izquierdo I, Fernández R, Torrent J, Benito S, Net A, Jane F. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol. 1991; 40: 297-302.
17. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993; 21: 172-173. (Pubitemid 23132762)
18. Lugo G, Castañeda-Hernández G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med. 1997; 25: 806-811. (Pubitemid 27249158)
19. Howard JB, McCracken GH Jr. Pharmacological evaluation of amikacin in neonates. Antimicrob Agents Chemother. 1975; 8: 86-90.
20. Sardemann H, Colding H, Hendel J, Kampmann JP, Hvidberg EF, Vejlsgaard R. Kinetics and dose calculations of amikacin in the newborn. Clin Pharmacol Ther. 1976; 20: 59-66.
21. Myers MG, Roberts RJ, Mirhij NJ. Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum of infants. Antimicrob Agents Chemother. 1977; 11: 1027-1032. (Pubitemid 8129666)
22. Lanao JM, Dominguez-Gil A, Dominguez-Gil AA, Málaga S, Crespo M, Nuño F. Modification in the pharmacokinetics of amikacin during development. Eur J Clin Pharmacol. 1982; 23: 155-160. (Pubitemid 12068944)
23. Roz JC, Tohier C, Rigal E, Drugeon B, Mouzard A. Posology of amikacin in newborn infants, adapted to the postconceptional age. Arch Fr Pediatr. 1989; 46: 375-379. (Pubitemid 19167584)
24. Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother. 1990; 34: 265-268. (Pubitemid 20046878)
25. Petersen PO, Wells TG, Kearns GL. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther. 1991; 16: 203-211.
26. Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther. 1993; 20: 167-173.
27. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977; 5: 445-479. (Pubitemid 8224518)
28. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20: 511-528.
29. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998; 15: 1463-1468. (Pubitemid 28427937)
30. Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol. 1998; 46: 229-236. (Pubitemid 28404835)
31. Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol. 2003; 55: 252-263. (Pubitemid 36390755)
32. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996; 42: 747-756. (Pubitemid 26417617)
33. Zaera S, Hermida J, Tutor JC. Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase Pharmacokinetic Systems. Ther Drug Monit. 2002; 24: 696-700. (Pubitemid 35379521)
34. Hammett-Stabler CA, Johns T; National Academy of Clinical Biochemistry. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem. 1998; 44: 1129-1140.
35. Lacarelle B, Granthil C, Manelli JC, Bruder N, Francois G, Cano JP. Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function. Ther Drug Monit. 1987; 9: 154-160. (Pubitemid 17078114)
36. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother. 1998; 42: 849-856.
37. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother. 1996; 40: 1682-1689.
38. Kim HS, Sohn IJ, Min DI. Pharmacokinetics of amikacin and effect of ascites in Korean patients. Am J Health Syst Pharm. 2002; 59: 1855-1857.
39. Joubert P, Bressolle F, Gouby A, Douçot PY, Saissi G, Gomeni R. A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen. Eur J Drug Metab Pharmacokinet. 1999; 24: 39-46. (Pubitemid 29286642)
40. Fernández de Gatta MM, Mendez ME, Romano S, Calvo MV, Dominguez-Gil A, Lanao JM. Pharmacokinetics of amikacin in intensive care unit patients. J Clin Pharm Ther. 1996; 21: 417-421. (Pubitemid 27252866)
41. Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother. 1999; 44: 235-242. (Pubitemid 29389287)
42. Ducher M, Maire P, Cerutti C, Bourhis Y, Foltz F, Sorensen P, Jelliffe R, Fauvel JP. Renal elimination of amikacin and the aging process. Clin Pharmacokinet. 2001; 40: 947-953. (Pubitemid 34066689)
43. Romano S, González P, Tejada P, Antón J, Aguado JM, Lanao JM. Influence of diagnostic and treatment factors in the population pharmacokinetics of gentamicin. J Clin Pharm Ther. 1998; 23: 141-148. (Pubitemid 28464382)